[Prevention of ossification after total hip endoprosthesis with indomethacin and its effect on gastric mucosa].
The administration of indomethacin as a prophylactic against heterotopic ossification following the implantation of total hip-joint endoprosteses entails the risk of gastrointestinal side-effects. A prospective randomized study set out to determine the effectiveness of ranitidine and sucralfate as a secondary treatment for the protection of the stomach. Comparison with a placebo group monitored at the same time confirmed the efficacy of both medicaments. Both ranitidine (2 x 150 mg) and sucralfate (4 x 1 g) were able to prevent the occurrence of ulcers of the mucous membrane of both stomach and duodenum. Thanks to postoperative prophylactic treatment with indomethacin (2 x 50 mg for 3 weeks), there were no serious ossifications (degree II or III according to Arqu).
Metzenroth
H
H
Allgem. Orthop. Abteilung, Orthopädisches Krankenhaus Wien-Gersthof.
Publig
W
W
Knahr
K
K
Zandl
C
C
Kuchner
G
G
Carda
C
C
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004305:Dose-Response Relationship, Drug; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects*; D005773:Gastroscopy; D006622:Hip Prosthesis; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009999:Ossification, Heterotopic / Q000209:etiology / Q000517:prevention & control; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D011899:Ranitidine / Q000008:administration & dosage; D013392:Sucralfate / Q000008:administration & dosage
D013392:Sucralfate; D011899:Ranitidine; D007213:Indomethacin
Ossifikationsprophylaxe nach Hüfttotalendoprothesen mit Indomethacin und ihr Einfluss auf die Magenschleimhaut.